Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Locally Advanced Lung Carcinoma: early-phase trial registry
3 of 3 indexed Locally Advanced Lung Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Locally Advanced Lung Carcinoma: 3 US clinical trials tracked, 3 recruiting.
Locally Advanced Lung Carcinoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Jun Zhang, MD, PhD, running 1 of these trials.
Enrollment posture brief
Registry condition locally-advanced-lung-carcinoma
OPEN 3 | RECR 100% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Locally Advanced Lung Carcinoma lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Locally Advanced Lung Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Locally Advanced Lung Carcinoma is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Mayo Clinic
NCT06075524
Esomeprazole and Radiation Induced Esophagitis
Rush University Medical Center
NCT06120803
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
Jun Zhang, MD, PhD
NCT04680377
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Locally Advanced Lung Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Locally Advanced Lung Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Locally Advanced Lung Carcinoma page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Locally Advanced Lung Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jun Zhang, MD, PhD sponsors the most Locally Advanced Lung Carcinoma trials on record, review their full trial history before evaluating a specific study. See Jun Zhang, MD, PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced Lung Carcinoma condition card totals 3 registered trials; most-linked intervention Esomeprazole 40 mg; top US site state Rhode Island. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.